文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

女性和男性肠易激综合征患者粪便微生物群移植的反应。

Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome.

机构信息

Department of Medicine, Stord Helse-Fonna Hospital, Stord 5416, Norway.

Genetic Analysis AS, Oslo 0485, Norway.

出版信息

World J Gastroenterol. 2021 May 14;27(18):2219-2237. doi: 10.3748/wjg.v27.i18.2219.

DOI:10.3748/wjg.v27.i18.2219
PMID:34025075
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8117742/
Abstract

BACKGROUND: Faecal microbiota transplantation (FMT) seems to be a promising treatment for irritable bowel syndrome (IBS) patients. In Western countries (United States and Europe), there is a female predominance in IBS. A sex difference in the response to FMT has been reported recently in IBS patients. AIM: To investigate whether there was a sex difference in the response to FMT in the IBS patients who were included in our previous randomized controlled trial of the efficacy of FMT. METHODS: The study included 164 IBS patients who participated in our previous randomized controlled trial. These patients had moderate-to-severe IBS symptoms belonging to the IBS-D (diarrhoea-predominant), IBS-C (constipation-predominant) and IBS-M (mixed) subtypes, and had not responded to the National Institute for Health and Care Excellence (NICE)-modified diet. The belonged in three groups: placebo (own faeces), and active treated group (30-g or 60-g superdonor faeces). The patients completed the IBS severity scoring system (IBS-SSS), Fatigue Assessment Scale (FAS) and the IBS quality of life scale (IBS-QoL) questionnaires at the baseline and 2 wk, 1 mo and 3 mo after FMT. They also provided faecal samples at the baseline and 1 mo after FMT. The faecal bacteria profile and dysbiosis were determined using the 16S rRNA gene polymerase chain reaction DNA amplification covering V3-V9; probe labelling by single nucleotide extension and signal detection. The levels of short-chain fatty acids (SCFAs) were determined by gas chromatography and flame ionization. RESULTS: There was no sex difference in the response to FMT either in the placebo group or active treated group. There was no difference between females and males in either the placebo group or actively treated groups in the total score on the IBS-SSS, FAS or IBS-QoL, in dysbiosis, or in the faecal bacteria or SCFA level. However, the response rate was significantly higher in females with diarrhoea-predominant (IBS-D) than that of males at 1 mo, and 3 mo after FMT. Moreover, IBS-SSS total score was significantly lower in female patients with IBS-D than that of male patients both 1 mo and 3 mo after FMT. CONCLUSION: There was no sex difference in the response to FMT among IBS patients with moderate-to-severe symptoms who had previously not responded to NICE-modified diet. However, female patients with IBS-D respond better and have higher reduction of symptoms than males after FMT.

摘要

背景：粪便微生物移植（FMT）似乎是治疗肠易激综合征（IBS）患者的一种有前途的方法。在西方国家（美国和欧洲），IBS 患者中女性居多。最近有报道称，IBS 患者对 FMT 的反应存在性别差异。

目的：研究在我们之前的 FMT 疗效随机对照试验中纳入的 IBS 患者中，FMT 的反应是否存在性别差异。

方法：该研究纳入了 164 名参加我们之前的 FMT 疗效随机对照试验的 IBS 患者。这些患者患有中重度 IBS 症状，属于 IBS-D（腹泻为主型）、IBS-C（便秘为主型）和 IBS-M（混合型）亚型，且对国家卫生与保健卓越研究所（NICE）改良饮食无反应。这些患者分为三组：安慰剂（自身粪便）和活性治疗组（30g 或 60g 超级供体粪便）。患者在 FMT 前、2 周、1 个月和 3 个月时完成 IBS 严重程度评分系统（IBS-SSS）、疲劳评估量表（FAS）和 IBS 生活质量量表（IBS-QoL）问卷，并在 FMT 前和 1 个月时提供粪便样本。使用 16S rRNA 基因聚合酶链反应 DNA 扩增覆盖 V3-V9 来确定粪便细菌谱和失调；通过单核苷酸延伸和信号检测进行探针标记。通过气相色谱和火焰电离法测定短链脂肪酸（SCFA）水平。

结果：无论是在安慰剂组还是活性治疗组，FMT 的反应均与性别无关。在安慰剂组或活性治疗组中，女性和男性在 IBS-SSS、FAS 或 IBS-QoL 的总分、失调或粪便细菌或 SCFA 水平方面均无差异。然而，在 FMT 后 1 个月和 3 个月时，腹泻为主型（IBS-D）女性的应答率明显高于男性。此外，在 FMT 后 1 个月和 3 个月时，IBS-D 女性患者的 IBS-SSS 总分明显低于男性患者。

结论：在先前对 NICE 改良饮食无反应的中重度症状 IBS 患者中，FMT 的反应与性别无关。然而，FMT 后，IBS-D 女性患者的反应更好，症状缓解程度更高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/75345e7536de/WJG-27-2219-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/fd069f635470/WJG-27-2219-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/f4cc5fdb4a64/WJG-27-2219-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/496ac09ac5c9/WJG-27-2219-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/0e891ea63c7c/WJG-27-2219-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/4cc9cde7e9d5/WJG-27-2219-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/9258aff8a549/WJG-27-2219-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/93dc83efc918/WJG-27-2219-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/25b84563eca5/WJG-27-2219-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/3dea0343a3e1/WJG-27-2219-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/301a1dbf71f1/WJG-27-2219-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/b21985fb586e/WJG-27-2219-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/75345e7536de/WJG-27-2219-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/fd069f635470/WJG-27-2219-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/f4cc5fdb4a64/WJG-27-2219-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/496ac09ac5c9/WJG-27-2219-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/0e891ea63c7c/WJG-27-2219-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/4cc9cde7e9d5/WJG-27-2219-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/9258aff8a549/WJG-27-2219-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/93dc83efc918/WJG-27-2219-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/25b84563eca5/WJG-27-2219-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/3dea0343a3e1/WJG-27-2219-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/301a1dbf71f1/WJG-27-2219-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/b21985fb586e/WJG-27-2219-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6da/8117742/75345e7536de/WJG-27-2219-g012.jpg

相似文献

[1]
Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome.

World J Gastroenterol. 2021-5-14

[2]
The fecal microbiota transplantation response differs between patients with severe and moderate irritable bowel symptoms.

Scand J Gastroenterol. 2022-9

[3]
Changes in fecal short-chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome.

Neurogastroenterol Motil. 2021-2

[4]
Increasing the transplant dose and repeating faecal microbiota transplantation results in the responses of male patients with IBS reaching those of females.

Scand J Gastroenterol. 2024-4

[5]
Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels.

Scand J Gastroenterol. 2019-6

[6]
Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study.

Gut. 2018-7-6

[7]
Irritable bowel syndrome patients who are not likely to respond to fecal microbiota transplantation.

Neurogastroenterol Motil. 2022-9

[8]
Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial.

Lancet Gastroenterol Hepatol. 2017-11-1

[9]
Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS).

Nutrients. 2019-6-24

[10]
Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.

Lancet Gastroenterol Hepatol. 2019-7-17

引用本文的文献

[1]
Sex hormone-binding globulin and sex-specific association between irritable bowel syndrome and type 2 diabetes: a prospective cohort study.

Nutr J. 2025-7-10

[2]
Fecal microbiota transplantation-current perspective on human health.

Front Med (Lausanne). 2025-3-14

[3]
Advances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases.

Adv Sci (Weinh). 2025-4

[4]
Dietary Interventions in Irritable Bowel Syndrome: A Systematic Review of Clinical Outcomes, Microbiota Changes, and Inflammatory Markers.

Cureus. 2024-9-30

[5]
Sex-specific post-inflammatory dysbiosis mediates chronic visceral pain in colitis.

Gut Microbes. 2024

[6]
The Role of Nondigestible Oligosaccharides in Alleviating Human Chronic Diseases by Regulating the Gut Microbiota: A Review.

Foods. 2024-7-8

[7]
Changes in Fecal Short-Chain Fatty Acids in IBS Patients and Effects of Different Interventions: A Systematic Review and Meta-Analysis.

Nutrients. 2024-5-31

[8]
Gut Dysbiosis in Irritable Bowel Syndrome: A Narrative Review on Correlation with Disease Subtypes and Novel Therapeutic Implications.

Microorganisms. 2023-9-22

[9]
From-Toilet-to-Freezer: A Review on Requirements for an Automatic Protocol to Collect and Store Human Fecal Samples for Research Purposes.

Biomedicines. 2023-9-28

[10]
Fecal microbiota transplantation for irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.

Front Immunol. 2023

本文引用的文献

[1]
Diagnosis and Treatment of Irritable Bowel Syndrome: A Review.

JAMA. 2021-3-2

[2]
Changes in fecal short-chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome.

Neurogastroenterol Motil. 2021-2

[3]
Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.

Gastroenterology. 2021-1

[4]
Fecal microbiota transplantation in gastrointestinal disorders: time for precision medicine.

Genome Med. 2020-6-30

[5]
Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome.

Aliment Pharmacol Ther. 2020-4-28

[6]
Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study.

Gut. 2019-12-18

[7]
Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.

Lancet Gastroenterol Hepatol. 2019-7-17

[8]
The Microbiome and Irritable Bowel Syndrome - A Review on the Pathophysiology, Current Research and Future Therapy.

Front Microbiol. 2019-6-10

[9]
The Effect of Allogenic Versus Autologous Fecal Microbiota Transfer on Symptoms, Visceral Perception and Fecal and Mucosal Microbiota in Irritable Bowel Syndrome: A Randomized Controlled Study.

Clin Transl Gastroenterol. 2019-4

[10]
The Super-Donor Phenomenon in Fecal Microbiota Transplantation.

Front Cell Infect Microbiol. 2019-1-21

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索